This whole thing with Amarex has been so unfortunate and a humongous setback. Sounds like there's nothing really on the horizon. I'm not even sure at if leronlimab is being used in an trials at the moment or when it will be put to a trial in cancer or nash. This year has been a wash and sounds like we have a long way to go to bring real value to shareholders. Wish I had sold when we went above $7 the second time around the time of the Nader interview where he said 'triple-digits' before the announcement that we failed the covid trial. I could then buy alot more shares at these prices. On the bright side, Arman sounded like a solid head for the company. Investing in cytodyn feels like deja vu of when I first invested in the company at these prices back in 2016. Hopefully it doesn't take another 4 years and a pandemic to see $5+ share price.
GLTA